Literature DB >> 15672272

No changes in event-related potentials with estrogen or estrogen plus progesterone treatment in healthy older hysterectomized women: results from a double-blind, placebo-controlled study.

V Walpurger1, R Pietrowsky, S Djahansouzi, O T Wolf.   

Abstract

RATIONALE: The potential to improve cognition in older women with estrogen or estrogen/progesterone therapy is currently a matter of intense debate. Only a few studies conducted so far have used electrophysiological indicators of cognitive information processing as outcome measures in randomised placebo controlled studies.
OBJECTIVES: This study was undertaken to measure changes in event-related potentials (ERPs) after short (4 weeks) or prolonged (24 weeks) hormone treatment in older women.
METHODS: A randomised, double-blind, placebo-controlled study in hysterectomized older women (aged 58-75 years) was performed (n = 51). The participants received orally estradiol (2 mg estradiol valerate), estradiol plus progesterone (100 mg micronized progesterone) or placebo for 24 weeks. Using four different paradigms, early and late ERPs were assessed at baseline and after 4 and 24 weeks of treatment.
RESULTS: Strong hormone increases were observed in the two active treatment groups. However, no significant effects on any of the assessed ERPs were observed in either of the two treatment groups. Similar non-significant findings were obtained for reaction time and error rate.
CONCLUSIONS: Estradiol or estradiol/progesterone treatment appears to have no strong effects on several ERP markers of information processing in older hysterectomized women. The current negative findings might suggest a reduced sensitivity of the aged brain to gonadal steroids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15672272     DOI: 10.1007/s00213-004-2090-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

Review 1.  Estrogen actions in the central nervous system.

Authors:  B S McEwen; S E Alves
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

2.  Estrogen as a treatment for Alzheimer disease.

Authors:  C D Toran-Allerand
Journal:  JAMA       Date:  2000-07-19       Impact factor: 56.272

3.  Acute influences of estrogen and testosterone on divergent and convergent thinking in postmenopausal women.

Authors:  Rosemarie Krug; Matthias Mölle; Christoph Dodt; Horst L Fehm; Jan Born
Journal:  Neuropsychopharmacology       Date:  2003-05-14       Impact factor: 7.853

4.  Effects of estrogen on memory function in surgically menopausal women.

Authors:  S M Phillips; B B Sherwin
Journal:  Psychoneuroendocrinology       Date:  1992-10       Impact factor: 4.905

5.  Meta-analysis of P300 normative aging studies.

Authors:  J Polich
Journal:  Psychophysiology       Date:  1996-07       Impact factor: 4.016

6.  The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females.

Authors:  T Duka; R Tasker; J F McGowan
Journal:  Psychopharmacology (Berl)       Date:  2000-04       Impact factor: 4.530

7.  Effects of patch or gel estrogen therapies on auditory brainstem response in surgically postmenopausal women: a prospective, randomized study.

Authors:  Salvatore Caruso; Luigi Maiolino; Carmela Agnello; Aldo Garozzo; Lucia Di Mari; Agostino Serra
Journal:  Fertil Steril       Date:  2003-03       Impact factor: 7.329

8.  Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats.

Authors:  R B Gibbs
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

9.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Stephen R Rapp; Mark A Espeland; Sally A Shumaker; Victor W Henderson; Robert L Brunner; JoAnn E Manson; Margery L S Gass; Marcia L Stefanick; Dorothy S Lane; Jennifer Hays; Karen C Johnson; Laura H Coker; Maggie Dailey; Deborah Bowen
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

10.  Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients.

Authors:  Bernd Saletu; Peter Anderer; Doris Gruber; Markus Metka; Johannes Huber; Gerda M Saletu-Zyhlarz
Journal:  Maturitas       Date:  2002-11-20       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.